Pharmaceutical
Filter News
Found 56,026 articles
-
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/24/2022
Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the fourth quarter and full year ended December 31, 2021, and a corporate update.
-
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
-
Moderna reported positive interim results from the Phase II/III KidCOVE trial of its mRNA COVID-19 vaccine for children six months to under two years and two to six years of age.
-
Pfizer is lining up a potential New Drug Application for an ulcerative colitis treatment for patients who are not seeing an improvement in their condition from currently available options.
-
Pfizer issued a statement on Monday regarding a voluntary recall of three of its products. The recall affects eleven lots of hypertension medications in total.
-
Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.
-
Locus Biosciences' CRISPR-Cas3-enhanced bacteriophage (crPhage™) product attacks harmful bacteria in the microbiome while sparing human cells.
-
The 4D pharma has shared positive interim results from its Phase I/II study of a combination therapeutic for the treatment of renal cell carcinoma (RCC).
-
Read on to learn more about three Series B and C financing rounds in the areas of genetically encoded small molecules, artificial intelligence (AI) and immuno-oncology (IO).
-
Longboard Pharmaceuticals to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit
3/23/2022
Longboard Pharmaceuticals, Inc. announced that members of its senior leadership team will participate virtually in the Rare and General Epilepsy and Seizure Disorders panel during Cantor Fitzgerald’s Rare Orphan Disease Summit, taking place March 29–30, 2022.
-
Cosmos Holdings CEO Provides Letter to Shareholders - Mar 23, 2022
3/23/2022
Cosmos Holdings, Inc., an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, provides the following letter to its shareholders from CEO Greg Siokas:
-
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
3/23/2022
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, announced the provisional notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.
-
Histogen Announces $4.75 Million Private Placement
3/23/2022
Histogen Inc. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500 shares of Series A redeemable convertible preferred stock and 2,500 shares of Series B redeemable convertible preferred stock.
-
Ascendis Pharma Announces Proposed Convertible Senior Notes Offering - Mar 23, 2022
3/23/2022
Ascendis Pharma A/S announced its intention to offer, subject to market and other conditions, US$500,000,000 aggregate principal amount of convertible senior notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
InnoCare Releases 2021 Annual Results and Business Highlights
3/23/2022
InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced 2021 annual results as of 31 December 2021.
-
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
3/23/2022
Flanders Investment and Trade is a Flemish government organization that facilitates investment projects in Flanders, a northern region of Belgium, and supports Flemish companies.
-
CareDx Announces XenoSure and XenoMap
3/23/2022
CareDx, Inc. announced the availability of XenoSure™ donor-derived cell-free DNA and XenoMap™ gene-expression profiling for investigational use in xenotransplantation research and post-xenotransplant clinical monitoring.
-
Beroni Group to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT
3/23/2022
Beroni Group announced that the Company has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
-
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
3/23/2022
atai Life Sciences N.V. announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update.
-
Sobi to cease ReFacto manufacturing in the first quarter of 2024
3/23/2022
Sobi® announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF®/Xyntha® has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025.